Project Updates

  • The OPTIONS Consortium objective is to develop a streamlined, adaptable product delivery platform for current and future ARV-based HIV prevention options, with a particular focus on women.

    • Plan 4 PrEP Toolkit offers support for oral PrEP introduction.
    • OPTIONS and IPM collaborate to make the case for the dapivirine ring.
    • Private sector landscape analysis supports country governments with oral PrEP implementation.
    • Community dialogues in Zimbabwe aim to understand oral PrEP readiness.
    • Regional guide for PrEP communications being developed.
    • South Africa expands oral PrEP launch to six more sites.
    • Operations research and KAP survey protocols approved.
    • New Resources Added to PrEPWatch.

    Read more >


  • POWER develops cost-effective and scalable models for implementation of ARV-based HIV prevention products for women.

    • My PrEP decision support tool in production with additional demand creation tools in development.
    • Final formative report completed.
    • Cohorts in Cape Town, Johannesburg, and Kisumu launched.

    Read more >


  • EMOTION increases uptake and correct and consistent use of ARV-based HIV prevention products by women at high risk of HIV infection using an end-user centered strategy.

    • Project VOGUE underway.

    Read more >


  • CHARISMA supports efforts to: increase women’s agency to safely use ARV-based HIV prevention, to engage male partners in HIV prevention, and to overcome harmful gender norms and reduce intimate partner violence (IPV).

    • Clinic- and community-based interventions continue.
    • Intervention evaluations and reporting planned.

    Read more >


  • GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance.

    • Drug-resistance testing in Kenya progresses.
    • GEMS prepares for drug-resistance testing in South Africa and Zimbabwe.
    • Genital swabs testing begins and assay development is underway.
    • Oral PrEP modeling continues.

    Read more >